Atara Biotherapeutics (ATRA)

Atara Biotherapeutics (ATRA) Stock Price & Analysis


ATRA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.20 - $5.64
Previous Close$0.65
Average Volume (3M)3.97M
Market Cap
Enterprise Value$12.13M
Total Cash (Recent Filing)$102.41M
Total Debt (Recent Filing)$48.51M
Price to Earnings (P/E)-0.2
Feb 27, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.77
Shares Outstanding101,922,250
10 Day Avg. Volume5,668,555
30 Day Avg. Volume3,966,223
Standard Deviation0.26
Financial Highlights & Ratios
Price to Book (P/B)-1.30
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.92
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.04
Price Target Upside640.97% Upside
Rating ConsensusHold
Number of Analyst Covering8



Ownership Overview

23.18% Mutual Funds
46.36% Other Institutional Investors
26.45% Public Companies and Individual Investors


What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest stock price was $0.20 and its highest was $5.64 in the past 12 months.
    What is Atara Biotherapeutics’s market cap?
    Currently, no data Available
    When is Atara Biotherapeutics’s upcoming earnings report date?
    Atara Biotherapeutics’s upcoming earnings report date is Feb 27, 2024 which is in 85 days.
      How were Atara Biotherapeutics’s earnings last quarter?
      Atara Biotherapeutics released its earnings results on Nov 01, 2023. The company reported -$0.66 earnings per share for the quarter, missing the consensus estimate of -$0.623 by -$0.037.
        Is Atara Biotherapeutics overvalued?
        According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Atara Biotherapeutics pay dividends?
          Atara Biotherapeutics does not currently pay dividends.
          What is Atara Biotherapeutics’s EPS estimate?
          Atara Biotherapeutics’s EPS estimate is -$0.46.
            How many shares outstanding does Atara Biotherapeutics have?
            Atara Biotherapeutics has 101,922,250 shares outstanding.
              What happened to Atara Biotherapeutics’s price movement after its last earnings report?
              Atara Biotherapeutics reported an EPS of -$0.66 in its last earnings report, missing expectations of -$0.623. Following the earnings report the stock price went down -2.326%.
                Which hedge fund is a major shareholder of Atara Biotherapeutics?
                Among the largest hedge funds holding Atara Biotherapeutics’s share is Baupost Group LLC. It holds Atara Biotherapeutics’s shares valued at 14M.


                  Company Description

                  Atara Biotherapeutics

                  Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.


                  Top 5 ETFs holding ATRA

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Schwab U.S. Broad Market ETF
                  iShares Russell 3000 ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold ATRA. The ETFs are listed according to market value of ATRA within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Adverum Biotechnologies
                  Fate Therapeutics
                  Kura Oncology

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis